U.S. Markets open in 5 hrs 3 mins

ViewRay, Inc. (VRAY)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
3.8400-0.0900 (-2.29%)
At close: 4:00PM EST
Sign in to post a message.
  • H
    Henry
    Certainly Vray has the backlog to show record revenues, it’s up to installation flow.
  • A
    Anonymous
    I am guessing that VRAY is going to end up in the Siemens book fairly soon. This latest agreement is just a get to know you step in an outright acquisition, kinda like dating before getting married. VRAY could go at about $13,00/share
    Bullish
  • C
    Cv
    Amsterdam UMC is a well-known and successful academic center.
  • T
    Tim
    Vray is reaching an inflection point which will promote quicker adoption for increased installation sites
  • B
    BigFin
    article on Seeking Alpha. Link to government web site doesn't work. can anyone provide confirmation from other sources? I cant see anything on the Viewray web site

    https://seekingalpha.com/news/3618446-viewray-up-9-on-va-contract-for-imaging-gear
    ViewRay (VRAY +9.0%) perks up on average volume in apparent response to a post on U.S. government website that it has been awarded a VA contract valued at ~$6.1M for its MRIdian Linac Systems..
    ViewRay (VRAY +9.0%) perks up on average volume in apparent response to a post on U.S. government website that it has been awarded a VA contract valued at ~$6.1M for its MRIdian Linac Systems..
    seekingalpha.com
  • T
    Tim
    I’m raising buy Target price to $4 on points taken from the CC
  • J
    Jon
    ViewRay is focused on giving clinicians new and more effective ways to treat cancer using radiation. Its approach uses MRI-based technology to provide real-time imaging that clearly defines the targeted tumor from the surrounding soft tissue and other critical organs during radiation treatment. With this groundbreaking offering, why have shares dipped 25% year-to-date?
    The share price decline comes on the heels of its preliminary Q4 results. VRAY announced that it expects quarterly sales of $17 million, landing very close to the consensus estimate. However, new orders largely disappointed, with this figure coming in at $21 million. As this is down from $49 million in the prior-year quarter, it’s no wonder investors have been concerned. It also didn’t help that VRAY burned through about $3 million in cash.
    That isn’t to say investors should give up on the healthcare name. Piper Sandler’s Matthew O'Brien did acknowledge the result was unexpected “as momentum in the order book appeared to have been building with eight orders (three upgrades) last quarter.” However, he argues that the soft order figure is indicative of “standard lumpiness capital equipment sales”, which should improve in the coming quarters.
    “Although we do not expect this to be the last bump in the road, we remain highly confident in the utility of the MRIdian as the best technology to treat cancer patients, and we believe it will yield significant share-taking over the next couple of years,” O’Brien commented. He added, “We believe today’s dip represents a buying opportunity to investors willing to weather some quarterly volatility...”
    As recent investments from heavyweights Medtronic and Elekta boosted its capital, VRAY should be able to improve system install times as well as access potential hospital targets for the MRIdian system. Based on all of these factors, the five-star analyst maintained an Overweight rating and $6 price target. At this target, shares could soar 89% in the next twelve months. (To watch O’Brien’s track record, click here)
    Like O’Brien, other Wall Street analysts are staying on board. 6 Buys and a single Hold issued in the last three months add up to a Strong Buy analyst consensus. In addition, the $6.71 average price target implies 112% upside potential. (See ViewRay stock analysis on TipRanks)
  • H
    Hamiltonian
    I was surprised VRAY was down on Monday after the VAR buy out, but it certainly turned around today. I suppose some people though their business would get more competitive with VAR in the hands of Siemens. That is not how I looked at it. I believe the mr-guided Linac is a better mousetrap. VAR does not have one and stands to lose share if that is where the market goes. They don't have the financial resources to buy VRAY themselves, and any crash program to build their own MR-Linac would take years and money. Therefore, I think they read the tea leaves and decided to take the money from Siemens. Therefore, I view the VAR takeover as a validation MR-Linac, and therefore a validation of VRAY's strategy. I believe this will put some some takeout value into VRAY stock, and that is what happened today. It would make little sense for VRAY to sell out at this point when their franchise value is only going to improve as MR-Linac continues to take ground. If data comes from the various clinical studies underway in 2021, as the company suggested on their call, and that data is supportive of the excellent outcomes shown in smaller, earlier studies in Amsterdam and elsewhere, 2021 could be a very strong year for orders. The 12% short interest will need to cover at some point as the story progresses. Odds of a stumble are not insignificant, given the early stage and the covid induced disfunction in the hospital world. Yet this quarter was first without an disappointment since the new management team took over and completely restructured the company's plans of market development. Going forward, investors should BTFD's when and if they occur. Lots of unknowables as far as timing, but if my interpretation of VAR's decision to sell is correct, the risk reward of an 18 month investment at this level is compelling.
  • D
    Deckard
    Elekta's MR Linac is selling well and Varian has their own system coming out soon. Varian is the 800lbs gorilla that dominates this market. The biggest issue this company is going to face is the upcoming change in reimbursement next year or the year after. Changing to an episodic pay model will hurt the specialty device systems. ViewRay's treatments are unique but they take way too long. I work in this industry and the market they're in is changing in an unfavorable way for them. They will all have to lobby to get their own CPT codes to receive additional reimbursement for MR guidance to compete. The difference though is that Varian and Elekta can offset slower sales as they have more products lines where as ViewRay does not.
  • Y
    YYZ
    To put this "miss" into perspective, with ~22m+ shares short before the report and a drop from ~$9.50 to $3 or a drop of $6.50 total, the shorts have the opportunity to pocket $143m+ which is way more than all their "orders" and now pushing toward half the market cap of the company for now.
  • Y
    Yahoo Finance Insights
    ViewRay is up 13.15% to 3.70
  • A
    Adolfo
    Option movement at end of Thursday give the idea of insider information.
    Investing $300,000 and putting the strike price at $.5.70 makes a nice income, but seeing that weak hands sell gives the opportunity to make purchases in 100/100 lowering the price up to the actual and making more than $2MM of income.
    I guess by next Friday the price will be above $5 but if SEC make some investigation this price could be reached before Friday
  • J
    John
    Back invested in this. Picked up 40K shares at average of $1.21. I know the company has it's issues, but the share price is way too cheap.
  • A
    ALFRED
    As great as today's news is, the $212 MILLION backlog is a real cause for concern. Eleckta is breathing down their back so tjhey better get moving!
  • A
    ALFRED
    VRAY expanding into Denver area to add 200+ jobs; diesn't say what kind of jobs but my guess would be fabrication of the units to help with the GD backlog....growing companies expand, so this is very positive news.
  • C
    Caribbeanknight1
    What is up with the Shorts? The 6/29 report was just released and shares short increased to 13,625,746. That 1.3 million more in just two weeks
  • A
    ALFRED
    All these lawyers piling on is really indicative of the state of our country: a company invents a technolgy to save and prolong life, but their stock goes down, so now lawyers can make money by beating the company up and forcing it to use precious resources to defend itself against wild accusations - instead of using its capital to further its development. Very sad indeed....
    Bullish
  • C
    Caribbeanknight1
    How big of a deal is this? A nice reaction in the AH session but so far only 25,000 shares traded. Sweeping changes and all three new additions have experience growing and selling companies.
  • A
    ALFRED
    I'm not sure if many on the board really KNOW what Meridian is all about; it is similary to Cyberknife - which uses gold fiducials to track the tumor - in that it delivers targeted radiation. However, Meridian tracks the tumor in REAL TIME as the patient is lying on the table. The beam only turns on when the tumor is in the target area AND NOTHING ELSE IS IN THE WAY!! Cyberknife can track a tumor using the beacons (fiducials) imnplanted around the cancer, but if another organ moves in the way because of intestinal gas or peristalsis or respiration, the beam does NOT turn OFF because it can't "SEE" that there is healthy tissue in the way, so the radiation passes thru it and then into the tumor. This type of treatment is faster, no doubt, since a specific amount of radiation is delivered in a specified period of time. But healthy tissue can also be irradiated in the process leading to possibly other cancers or necrosis. Meridian takes a LOT longer, since the beam may turn on and off many , many times during the course of treatment.
    During a recent consultation with a radiation oncologist for prostate cancer, I asked him why he wasn't considering using Meridian Linac. He told me bluntly something to the effect: "Why would I want to use a machine that takes SOOOO long to do the treatment? You know, time really IS money. I can see ten patients using Cyberknife while I may only be able to see five using Meridian...." So even though the technology may be superior, the bottom line is how much money can you make? OK, I get that, but which treatment would YOU rather have if given the choice??
    Bullish